Target intelligence / Profile preview

Thorium-227 (Th-227)

Target: Th-227
Molecular classification: Radioactive isotope, Small molecule, Alpha emitter

Overview

Thorium-227 is a radioactive isotope of thorium, classified as a small molecule and an alpha particle emitter. It has gained significant attention in the field of targeted radiotherapy, particularly for cancer treatment, due to its unique physical and radiological properties. Once localized at the tumor site, the emitted alpha particles destroy malignant cells through direct DNA damage.

Other names: 227Th

Mechanism of action

Emission of alpha particles causing double-strand DNA breaks in targeted cells

Biological functions

Induction of DNA damageCell deathIonizing radiation source

Disease associations

Cancer therapy

Safety considerations

Radiation exposureOff-target toxicityRisk of secondary malignancies

Beyond the preview

Go deeper on Thorium-227 (Th-227).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thorium-227 (Th-227).

Explore the full profile